Back to first-pass browser

First-pass extracted concept

mitochondrial apoptotic priming

Candidate: concept label1 source documents3 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1assay findingsupports2025Source 1DOIPubMed

BH3 profiling assessments have revealed that therapy-induced senescent cancer cells are globally less primed for apoptosis than their proliferating precursors.

Quoted textsource-backed
recent assessments of mitochondrial apoptotic signaling via BH3 profiling ... have revealed that TIS cancer cells are globally less primed for apoptosis than their proliferating precursors
Claim 2limitationsupports2025Source 1DOIPubMed

Mitochondrial apoptotic priming in target therapy-induced senescent cancer cells may limit the success of CAR-T/NK living drugs.

Quoted textsource-backed
A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells.
Claim 3mechanistic insightsupports2025Source 1DOIPubMed

Pre-existing mitochondrial priming and anti-apoptotic dependencies of parental non-senescent cells are retained after senescence induction, suggesting an inherited mitochondrial memory.

Quoted textsource-backed
the pre-existing priming and anti-apoptotic addictions of parental, non-senescent cells, are retained upon induction of senescence. This suggests an "inherited" mitochondrial memory